References

1. Ishino, Y.; Shinagawa, H.; Makino, K.; Amemura, M.; Nakata, A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 1987, 169, 5429–5433.
2. Riehle, M.M.; Bennett, A.F.; Long, A.D. Genetic architecture of thermal adaptation in Escherichia coli. Proc. Natl. Acad. Sci. USA 2001, 98, 525–530.
3. Makarova, K.S.; Haft, D.H.; Barrangou, R.; Brouns, S.J.J.; Charpentier, E.; Horvath, P.; Moineau, S.; Mojica, F.J.M.; Wolf, Y.I.; Yakunin, A.F.; et al. Evolution and classification of the CRISPR—Cas systems. Nat. Rev. Microbiol. 2011, 9, 467–477.
4. DeBoy, R.T.; Mongodin, E.F.; Emerson, J.B.; Nelson, K.E. Chromosome Evolution in the Thermotogales: Large-Scale Inversions and Strain Diversification of CRISPR Sequences. J. Bacteriol. 2006, 188, 2364–2374.
5. Jansen, R.; van Embden, J.D.A.; Gaastra, W.; Schouls, L.M. Identification of genes that are associated with DNA repeats in prokaryotes. Mol. Microbiol. 2002, 43, 1565–1575.
6. Mojica, F.J.M.; Diez-Villasenor, C.; Soria, E.; Juez, G. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Mol. Microbiol. 2000, 36, 244–246.
7. Pourcel, C.; Salvignol, G.; Vergnaud, G. CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology 2005, 151, 653–663.
8. Hille, F.; Richter, H.; Wong, S.P.; Bratovič, M.; Ressel, S.; Charpentier, E. The Biology of CRISPR-Cas: Backward and Forward. Cell 2018, 172, 1239–1259.
9. Makarova, K.S.; Wolf, Y.I.; Iranzo, J.; Shmakov, S.A.; Alkhnbashi, O.S.; Brouns, S.J.J.; Charpentier, E.; Cheng, D.; Haft, D.H.; Horvath, P.; et al. Evolutionary classification of CRISPR–Cas systems: A burst of class 2 and derived variants. Nat. Rev. Microbiol. 2020, 18, 67–83.
10. Makarova, K.S.; Wolf, Y.I.; Alkhnbashi, O.S.; Costa, F.; Shah, S.A.; Saunders, S.J.; Barrangou, R.; Brouns, S.J.J.; Charpentier, E.; Haft, D.H.; et al. An updated evolutionary classification of CRISPR—Cas systems. Nat. Rev. Microbiol. 2015, 13, 722–736.
11. Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraffini, L.A.; et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science 2013, 339, 819–823.
12. Jinek, M.; Chylinski, K.; Fonfara, I.; Hauer, M.; Doudna, J.A.; Charpentier, E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science 2012, 337, 816–821.
13. Mali, P.; Yang, L.; Esvelt, K.M.; Aach, J.; Guell, M.; DiCarlo, J.E.; Norville, J.E.; Church, G.M. RNA-Guided Human Genome Engineering via Cas9. Science 2013, 339, 823–826.
14. Barrangou, R. CRISPR-Cas systems and RNA-guided interference: CRISPR-Cas systems and RNA-guided interference. WIREs RNA 2013, 4, 267–278.
15. Bhaya, D.; Davison, M.; Barrangou, R. CRISPR-Cas Systems in Bacteria and Archaea: Versatile Small RNAs for Adaptive Defense and Regulation. Annu. Rev. Genet. 2011, 45, 273–297.
16. Yosef, I.; Goren, M.G.; Qimron, U. Proteins and DNA elements essential for the CRISPR adaptation process in Escherichia coli. Nucleic Acids Res. 2012, 40, 5569–5576.
17. Nuñez, J.K.; Kranzusch, P.J.; Noeske, J.; Wright, A.V.; Davies, C.W.; Doudna, J.A. Cas1–Cas2 complex formation mediates spacer acquisition during CRISPR–Cas adaptive immunity. Nat. Struct. Mol. Biol. 2014, 21, 528–534.
18. Heler, R.; Samai, P.; Modell, J.W.; Weiner, C.; Goldberg, G.W.; Bikard, D.; Marraffini, L.A. Cas9 specifies functional viral targets during CRISPR–Cas adaptation. Nature 2015, 519, 199–202.
19. Deltcheva, E.; Chylinski, K.; Sharma, C.M.; Gonzales, K.; Chao, Y.; Pirzada, Z.A.; Eckert, M.R.; Vogel, J.; Charpentier, E. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 2011, 471, 602–607.
20. Thurtle-Schmidt, D.M.; Lo, T.-W. Molecular biology at the cutting edge: A review on CRISPR/CAS9 gene editing for undergraduates: A Review on CRISPR/CAS9 Gene Editing for Undergraduates. Biochem. Mol. Biol. Educ. 2018, 46, 195–205.
21. Gasiunas, G.; Barrangou, R.; Horvath, P.; Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci. USA 2012, 109, E2579–E2586.
22. Anders, C.; Niewoehner, O.; Duerst, A.; Jinek, M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 2014, 513, 569–573.
23. Jinek, M.; Jiang, F.; Taylor, D.W.; Sternberg, S.H.; Kaya, E.; Ma, E.; Anders, C.; Hauer, M.; Zhou, K.; Lin, S.; et al. Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. Science 2014, 343, 1247997.
24. Nishimasu, H.; Ran, F.A.; Hsu, P.D.; Konermann, S.; Shehata, S.I.; Dohmae, N.; Ishitani, R.; Zhang, F.; Nureki, O. Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA. Cell 2014, 156, 935–949.
25. Rodriguez-Rodriguez, D.; Ramirez-Solis, R.; Garza-Elizondo, M.; Garza-Rodriguez, M.; Barrera-Saldana, H. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review). Int. J. Mol. Med. 2019.
26. Biagioni, A.; Chillà, A.; Andreucci, E.; Laurenzana, A.; Margheri, F.; Peppicelli, S.; Del Rosso, M.; Fibbi, G. Type II CRISPR/Cas9 approach in the oncological therapy. J. Exp. Clin. Cancer Res. 2017, 36, 80.
27. Jiang, F.; Doudna, J.A. CRISPR–Cas9 Structures and Mechanisms. Annu. Rev. Biophys. 2017, 46, 505–529.
28. Wyman, C.; Kanaar, R. DNA Double-Strand Break Repair: All’s Well that Ends Well. Annu. Rev. Genet. 2006, 40, 363–383.
29. Doench, J.G.; Fusi, N.; Sullender, M.; Hegde, M.; Vaimberg, E.W.; Donovan, K.F.; Smith, I.; Tothova, Z.; Wilen, C.; Orchard, R.; et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 2016, 34, 184–191.
30. Martinez-Lage, M.; Puig-Serra, P.; Menendez, P.; Torres-Ruiz, R.; Rodriguez-Perales, S. CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. Biomedicines 2018, 6, 105.
31. Petrucelli, N.; Daly, M.B.; Feldman, G.L. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet. Med. 2010, 12, 245–259.
32. Huen, M.S.Y.; Sy, S.M.H.; Chen, J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. Mol. Cell Biol. 2010, 11, 138–148.
33. Brzovic, P.S.; Rajagopal, P.; Hoyt, D.W.; King, M.-C.; Klevit, R.E. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat. Struct. Biol. 2001, 8, 833–837.
34. Brzovic, P.S.; Keeffe, J.R.; Nishikawa, H.; Miyamoto, K.; Fox, D.; Fukuda, M.; Ohta, T.; Klevit, R. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc. Natl. Acad. Sci. USA 2003, 100, 5646–5651.
35. Yamane, K.; Katayama, E.; Tsuruo, T. The BRCT Regions of Tumor Suppressor BRCA1 and of XRCC1 Show DNA End Binding Activity with a Multimerizing Feature. Biochem. Biophys. Res. Commun. 2000, 279, 678–684.
36. Liu, J.; Pan, Y.; Ma, B.; Nussinov, R. “Similarity Trap” in Protein-Protein Interactions Could Be Carcinogenic: Simulations of p53 Core Domain Complexed with 53BP1 and BRCA1 BRCT Domains. Structure 2006, 14, 1811–1821.
37. Kweon, J.; Jang, A.-H.; Shin, H.R.; See, J.-E.; Lee, W.; Lee, J.W.; Chang, S.; Kim, K.; Kim, Y. A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants. Oncogene 2020, 39, 30–35.
38. Corso, G.; Feroce, I.; Intra, M.; Toesca, A.; Magnoni, F.; Sargenti, M.; Naninato, P.; Caldarella, P.; Pagani, G.; Vento, A.; et al. BRCA1/2 germline missense mutations: A systematic review. Eur. J. Cancer Prev. 2018, 27, 279–286.
39. Roy, R.; Chun, J.; Powell, S.N. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer 2012, 12, 68–78.
40. Suwaki, N.; Klare, K.; Tarsounas, M. RAD51 paralogs: Roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin. Cell Dev. Biol. 2011, 22, 898–905.
41. Wong, M.W.; Nordfors, C.; Mossman, D.; Pecenpetelovska, G.; Avery-Kiejda, K.A.; Talseth-Palmer, B.; Bowden, N.A.; Scott, R.J. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res. Treat. 2011, 127, 853–859.
42. Prakash, R.; Zhang, Y.; Feng, W.; Jasin, M. Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins. Cold Spring Harb. Perspect. Biol. 2015, 7, a016600.
43. Feng, W.; Jasin, M. BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination. Nat. Commun. 2017, 8, 525.
44. Slamon, D.; Clark, G.; Wong, S.; Levin, W.; Ullrich, A.; McGuire, W. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science 1987, 235, 177–182.
45. Wang, H.; Sun, W. CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation. Cancer Lett. 2017, 385, 137–143.
46. Gutierrez, C.; Schiff, R. HER2: Biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 2011, 135, 55–62.
47. Yarden, Y. Biology of HER2 and Its Importance in Breast Cancer. Oncology 2001, 61, 1–13.
48. Moasser, M.M. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26, 6469–6487.
49. Home—My Cancer Genome. Available online: (accessed on 27 November 2020).
50. Welcome—IARC TP53 Database. Available online: (accessed on 27 November 2020).
51. Zhu, J.; Sammons, M.A.; Donahue, G.; Dou, Z.; Vedadi, M.; Getlik, M.; Barsyte-Lovejoy, D.; Al-awar, R.; Katona, B.W.; Shilatifard, A.; et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 2015, 525, 206–211.
52. Levine, A.J.; Berger, S.L. The interplay between epigenetic changes and the p53 protein in stem cells. Genes Dev. 2017, 31, 1195–1201.
53. Metastasis Has Multiple Origins and Occurs Early in Tumorigenesis. Cancer Discov. 2020, 10, 903.
54. Belotserkovskaya, R.; Raga Gil, E.; Lawrence, N.; Butler, R.; Clifford, G.; Wilson, M.D.; Jackson, S.P. PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1. Nat. Commun. 2020, 11, 819.
55. Xia, B.; Sheng, Q.; Nakanishi, K.; Ohashi, A.; Wu, J.; Christ, N.; Liu, X.; Jasin, M.; Couch, F.J.; Livingston, D.M. Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2. Mol. Cell 2006, 22, 719–729.
56. Ripperger, T.; Gadzicki, D.; Meindl, A.; Schlegelberger, B. Breast cancer susceptibility: Current knowledge and implications for genetic counselling. Eur. J. Hum. Genet. 2009, 17, 722–731.
57. Wiltshire, T.; Ducy, M.; Foo, T.K.; Hu, C.; Lee, K.Y.; Belur Nagaraj, A.; Rodrigue, A.; Gomes, T.T.; Simard, J.; Monteiro, A.N.A.; et al. Functional characterization of 84 PALB2 variants of uncertain significance. Genet. Med. 2020, 22, 622–632.
58. Cidado, J.; Wong, H.Y.; Rosen, D.M.; Cimino-Mathews, A.; Garay, J.P.; Fessler, A.G.; Rasheed, Z.A.; Hicks, J.; Cochran, R.L.; Croessmann, S.; et al. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget 2016, 7, 6281–6293.
59. Castéra, L.; Harter, V.; Muller, E.; Krieger, S.; Goardon, N.; Ricou, A.; Rousselin, A.; Paimparay, G.; Legros, A.; Bruet, O.; et al. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genet. Med. 2018, 20, 1677–1686.
60. Chapman, J.R.; Sossick, A.J.; Boulton, S.J.; Jackson, S.P. BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair. J. Cell Sci. 2012, 125, 3529–3534.
61. Endl, E.; Gerdes, J. The Ki-67 Protein: Fascinating Forms and an Unknown Function. Exp. Cell Res. 2000, 257, 231–237.
62. Cuzick, J.; Dowsett, M.; Pineda, S.; Wale, C.; Salter, J.; Quinn, E.; Zabaglo, L.; Mallon, E.; Green, A.R.; Ellis, I.O.; et al. Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. JCO 2011, 29, 4273–4278.
63. Cuylen, S.; Blaukopf, C.; Politi, A.Z.; Müller-Reichert, T.; Neumann, B.; Poser, I.; Ellenberg, J.; Hyman, A.A.; Gerlich, D.W. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature 2016, 535, 308–312.
64. Sobecki, M.; Mrouj, K.; Camasses, A.; Parisis, N.; Nicolas, E.; Llères, D.; Gerbe, F.; Prieto, S.; Krasinska, L.; David, A.; et al. The cell proliferation antigen Ki-67 organises heterochromatin. eLife 2016, 5, e13722.
65. Takagi, M.; Natsume, T.; Kanemaki, M.T.; Imamoto, N. Perichromosomal protein Ki67 supports mitotic chromosome architecture. Genes Cells 2016, 21, 1113–1124.
66. Sobecki, M.; Mrouj, K.; Colinge, J.; Gerbe, F.; Jay, P.; Krasinska, L.; Dulic, V.; Fisher, D. Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels. Cancer Res. 2017, 77, 2722–2734.
67. Miller, I.; Min, M.; Yang, C.; Tian, C.; Gookin, S.; Carter, D.; Spencer, S.L. Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence. Cell Rep. 2018, 24, 1105–1112.e5.
68. Dexter, D.L.; Kowalski, H.M.; Blazar, B.A.; Fligiel, Z.; Vogel, R.; Heppner, G.H. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978, 38, 3174–3181.
69. Mrouj, K.; Singh, P.; Sobecki, M.; Dubra, G.; Al Ghoul, E.; Aznar, A.; Prieto, S.; Pirot, N.; Bernex, F.; Bordignon, B.; et al. Ki-67 promotes sequential stages of tumourigenesis by enabling cellular plasticity. Cancer Biol. 2019.
70. Redig, A.J.; McAllister, S.S. Breast cancer as a systemic disease: A view of metastasis. J. Intern. Med. 2013, 274, 113–126.
71. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2002, 2, 563–572.
72. Ocaña, O.H.; Córcoles, R.; Fabra, Á.; Moreno-Bueno, G.; Acloque, H.; Vega, S.; Barrallo-Gimeno, A.; Cano, A.; Nieto, M.A. Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1. Cancer Cell 2012, 22, 709–724.
73. Maitra, A. Molecular envoys pave the way for pancreatic cancer to invade the liver. Nature 2019, 567, 181–182.
74. Massagué, J.; Obenauf, A.C. Metastatic colonization by circulating tumour cells. Nature 2016, 529, 298–306.
75. Kalluri, R.; Neilson, E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Investig. 2003, 112, 1776–1784.
76. Nieto, M.A. The Ins and Outs of the Epithelial to Mesenchymal Transition in Health and Disease. Annu. Rev. Cell Dev. Biol. 2011, 27, 347–376.
77. Wellner, U.; Schubert, J.; Burk, U.C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11, 1487–1495.
78. Kushwaha, P.P.; Gupta, S.; Singh, A.K.; Kumar, S. Emerging Role of Migration and Invasion Enhancer 1 (MIEN1) in Cancer Progression and Metastasis. Front. Oncol. 2019, 9, 868.
79. Kpetemey, M.; Dasgupta, S.; Rajendiran, S.; Das, S.; Gibbs, L.D.; Shetty, P.; Gryczynski, Z.; Vishwanatha, J.K. MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression. Mol. Cancer 2015, 14, 156.
80. Dasgupta, S.; Wasson, L.M.; Rauniyar, N.; Prokai, L.; Borejdo, J.; Vishwanatha, J.K. Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene 2009, 28, 2860–2872.
81. Dasgupta, S.; Cushman, I.; Kpetemey, M.; Casey, P.J.; Vishwanatha, J.K. Prenylated C17orf37 Induces Filopodia Formation to Promote Cell Migration and Metastasis. J. Biol. Chem. 2011, 286, 25935–25946.
82. Van Treuren, T.; Vishwanatha, J.K. CRISPR deletion of MIEN1 in breast cancer cells. PLoS ONE 2018, 13, e0204976.
83. Shen, F.; Zhang, Y.; Jernigan, D.L.; Feng, X.; Yan, J.; Garcia, F.U.; Meucci, O.; Salvino, J.M.; Fatatis, A. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol. Cancer Res. 2016, 14, 518–527.
84. Bazan, J.F.; Bacon, K.B.; Hardiman, G.; Wang, W.; Soo, K.; Rossi, D.; Greaves, D.R.; Zlotnik, A.; Schall, T.J. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385, 640–644.
85. Onitilo, A.A.; Engel, J.M.; Greenlee, R.T.; Mukesh, B.N. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin. Med. Res. 2009, 7, 4–13.
86. Gruber, I.; Fehm, T.; Taran, F.A.; Wallwiener, M.; Hahn, M.; Wallwiener, D.; Krawzyck, N.; Hoffmann, J.; Hartkopf, A.D. Disseminated tumor cells as a monitoring tool for adjuvant therapy in patients with primary breast cancer. Breast Cancer Res. Treat. 2014, 144, 353–360.
87. Cook, D.N.; Chen, S.-C.; Sullivan, L.M.; Manfra, D.J.; Wiekowski, M.T.; Prosser, D.M.; Vassileva, G.; Lira, S.A. Generation and Analysis of Mice Lacking the Chemokine Fractalkine. Mol. Cell. Biol. 2001, 21, 3159–3165.
88. Jamieson-Gladney, W.L.; Zhang, Y.; Fong, A.M.; Meucci, O.; Fatatis, A. The chemokine receptor CX3CR1 is directly involved in the arrest of breast cancer cells to the skeleton. Breast Cancer Res. 2011, 13, R91.
89. Xie, K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001, 12, 375–391.
90. Long, X.; Ye, Y.; Zhang, L.; Liu, P.; Yu, W.; Wei, F.; Ren, X.; Yu, J. IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review). Int. J. Oncol. 2016, 48, 5–12.
91. Stillie, R.; Farooq, S.M.; Gordon, J.R.; Stadnyk, A.W. The functional significance behind expressing two IL-8 receptor types on PMN. J. Leukoc. Biol. 2009, 86, 529–543.
92. Wuyts, A.; Van Osselaer, N.; Haelens, A.; Samson, I.; Herdewijn, P.; Ben-Baruch, A.; Oppenheim, J.J.; Proost, P.; Van Damme, J. Characterization of Synthetic Human Granulocyte Chemotactic Protein 2: Usage of Chemokine Receptors CXCR1 and CXCR2 and in Vivo Inflammatory Properties. Biochemistry 1997, 36, 2716–2723.
93. Saintigny, P.; Massarelli, E.; Lin, S.; Ahn, Y.-H.; Chen, Y.; Goswami, S.; Erez, B.; O’Reilly, M.S.; Liu, D.; Lee, J.J.; et al. CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma. Cancer Res. 2013, 73, 571–582.
94. Jin, K.; Pandey, N.B.; Popel, A.S. Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis. Oncotarget 2017, 8, 60210–60222.
95. Sun, X.; Cheng, G.; Hao, M.; Zheng, J.; Zhou, X.; Zhang, J.; Taichman, R.S.; Pienta, K.J.; Wang, J. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010, 29, 709–722.
96. Yang, M.; Zeng, C.; Li, P.; Qian, L.; Ding, B.; Huang, L.; Li, G.; Jiang, H.; Gong, N.; Wu, W. Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells. OncoTargets Ther. 2019, 12, 3849–3858.
97. Ganju, R.K.; Brubaker, S.A.; Meyer, J.; Dutt, P.; Yang, Y.; Qin, S.; Newman, W.; Groopman, J.E. The α-Chemokine, Stromal Cell-derived Factor-1α, Binds to the Transmembrane G-protein-coupled CXCR-4 Receptor and Activates Multiple Signal Transduction Pathways. J. Biol. Chem. 1998, 273, 23169–23175.
98. Miao, Z.; Luker, K.E.; Summers, B.C.; Berahovich, R.; Bhojani, M.S.; Rehemtulla, A.; Kleer, C.G.; Essner, J.J.; Nasevicius, A.; Luker, G.D.; et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. USA 2007, 104, 15735–15740.
99. Wang, J.; Shiozawa, Y.; Wang, J.; Wang, Y.; Jung, Y.; Pienta, K.J.; Mehra, R.; Loberg, R.; Taichman, R.S. The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer. J. Biol. Chem. 2008, 283, 4283–4294.
100. Zheng, K.; Li, H.-Y.; Su, X.-L.; Wang, X.-Y.; Tian, T.; Li, F.; Ren, G.-S. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. 2010, 29, 31.
101. Burns, J.M.; Summers, B.C.; Wang, Y.; Melikian, A.; Berahovich, R.; Miao, Z.; Penfold, M.E.T.; Sunshine, M.J.; Littman, D.R.; Kuo, C.J.; et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203, 2201–2213.
102. Wu, W.; Qian, L.; Dai, J.; Ding, B.; Chen, X. Expression of chemokine CXCL12 and its receptor (CXCR4 and CXCR7) in different molecular subtypes of human breast carcinoma and the clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2017, 42, 147–153.
103. Johnson, G.L. Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases. Science 2002, 298, 1911–1912.
104. Rattanasinchai, C.; Gallo, K. MLK3 Signaling in Cancer Invasion. Cancers 2016, 8, 51.
105. Cronan, M.R.; Nakamura, K.; Johnson, N.L.; Granger, D.A.; Cuevas, B.D.; Wang, J.-G.; Mackman, N.; Scott, J.E.; Dohlman, H.G.; Johnson, G.L. Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis. Oncogene 2012, 31, 3889–3900.
106. Jiang, X.; Xie, H.; Dou, Y.; Yuan, J.; Zeng, D.; Xiao, S. Expression and function of FRA1 protein in tumors. Mol. Biol. Rep. 2020, 47, 737–752.
107. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell 2010, 141, 52–67.
108. Rattanasinchai, C.; Llewellyn, B.J.; Conrad, S.E.; Gallo, K.A. MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells. Oncogenesis 2017, 6, e345.
109. Kohli, S.; Kohli, V. Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian J. Endocr. Metab. 2011, 15, 175.
110. Cody, J.J.; Rivera, A.A.; Lyons, G.R.; Yang, S.W.; Wang, M.; Sarver, D.B.; Wang, D.; Selander, K.S.; Kuo, H.-C.; Meleth, S.; et al. Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer. Cancer Gene 2010, 17, 893–905.
111. Sheridan, J.P. Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors. Science 1997, 277, 818–821.
112. Geerts, D.; Chopra, C.; Connelly, L. Osteoprotegerin: Relationship to Breast Cancer Risk and Prognosis. Front. Oncol. 2020, 10, 462.
113. Zhong, Z.; Niu, P.; Wang, M.; Huang, G.; Xu, S.; Sun, Y.; Xu, X.; Hou, Y.; Sun, X.; Yan, Y.; et al. Targeted disruption of sp7 and myostatin with CRISPR-Cas9 results in severe bone defects and more muscular cells in common carp. Sci. Rep. 2016, 6, 22953.
114. Kichev, A.; Eede, P.; Gressens, P.; Thornton, C.; Hagberg, H. Implicating Receptor Activator of NF-κB (RANK)/RANK Ligand Signalling in Microglial Responses to Toll-Like Receptor Stimuli. Dev. Neurosci. 2017, 39, 192–206.
115. Goswami, S.; Sharma-Walia, N. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: Implications in carcinogenesis. Oncotarget 2016, 7, 58953–58974.
116. Song, L.; Luo, Z.-Q. Post-translational regulation of ubiquitin signaling. J. Cell Biol. 2019, 218, 1776–1786.
117. Shearer, R.F.; Iconomou, M.; Watts, C.K.W.; Saunders, D.N. Functional Roles of the E3 Ubiquitin Ligase UBR5 in Cancer. Mol. Cancer Res. 2015, 13, 1523–1532.
118. Liao, L.; Song, M.; Li, X.; Tang, L.; Zhang, T.; Zhang, L.; Pan, Y.; Chouchane, L.; Ma, X. E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2017, 77, 2090–2101.
119. Mavaddat, N.; Barrowdale, D.; Andrulis, I.L.; Domchek, S.M.; Eccles, D.; Nevanlinna, H.; Ramus, S.J.; Spurdle, A.; Robson, M.; Sherman, M.; et al. Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol. Biomark. Prev. 2012, 21, 134–147.
120. Wilson, J.R.F.; Bateman, A.C.; Hanson, H.; An, Q.; Evans, G.; Rahman, N.; Jones, J.L.; Eccles, D.M. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J. Med. Genet. 2010, 47, 771–774.
121. Bouwman, P.; Aly, A.; Escandell, J.M.; Pieterse, M.; Bartkova, J.; van der Gulden, H.; Hiddingh, S.; Thanasoula, M.; Kulkarni, A.; Yang, Q.; et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 2010, 17, 688–695.
122. Ahmed, A.; Ashraf, D.; Bahaa, A.; El-Tayebi, H.; Adwan, H. Impact of CDK4 knock out using CRISPR/Cas9 gene editing technology on breast cancer progression. Eur. J. Cancer 2020, 138, S70–S71.
123. Xu, K.; Chen, G.; Li, X.; Wu, X.; Chang, Z.; Xu, J.; Zhu, Y.; Yin, P.; Liang, X.; Dong, L. MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Sci. Rep. 2017, 7, 41718.
124. Mendes de Almeida, R.; Bandarra, S.; Clara Ribeiro, A.; Mascarenhas, P.; Bekman, E.; Barahona, I. Inactivation of APOBEC3G gene in breast cancer cells using the CRISPR/Cas9 system. Ann. Med. 2019, 51, 40.
125. Heidary Arash, E.; Shiban, A.; Song, S.; Attisano, L. MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells. EMBO Rep. 2017, 18, 420–436.
126. Álvarez-Fernández, M.; Sanz-Flores, M.; Sanz-Castillo, B.; Salazar-Roa, M.; Partida, D.; Zapatero-Solana, E.; Ali, H.R.; Manchado, E.; Lowe, S.; VanArsdale, T.; et al. Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. Cell Death Differ. 2017.
127. Lin, A.; Giuliano, C.J.; Sayles, N.M.; Sheltzer, J.M. CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. eLife 2017, 6, e24179.
128. Tian, J.; Wang, V.; Wang, N.; Khadang, B.; Boudreault, J.; Bakdounes, K.; Ali, S.; Lebrun, J.-J. Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition. Breast Cancer Res. 2021, 23, 23.